New drug duo targets BRCA cancers in early trial
NCT ID NCT04673448
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This early-phase trial tests a combination of two drugs—niraparib and dostarlimab—in people with breast, pancreas, or ovarian cancers that have a BRCA gene mutation and have spread or can't be removed by surgery. Niraparib blocks a DNA repair process that cancer cells rely on, while dostarlimab helps the immune system attack tumors. The study aims to see how well this combo shrinks tumors and what side effects occur. It includes 18 adults who have already tried standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.